CRISPR Therapeutics AG CRSP is trading lower Wednesday after the company reported results from its Phase 1 CARBON trial of CTX110 in relapsed or refractory CD19+ B-cell malignancies.
“We are excited to share positive data from our CARBON trial, which show that CTX110 could offer patients with large B-cell lymphomas an immediately available ‘off-the-shelf’ therapy with efficacy similar to autologous CAR-T and a differentiated safety profile,” said Samarth Kulkarni, CEO of CRISPR Therapeutics.
Kulkarni continued, “Furthermore, we have the potential to improve upon already observed efficacy with a consolidation dosing strategy. Based on these encouraging results, we are planning to expand CARBON into a potentially registrational trial in the first quarter of 2022.”
CRISPR Therapeutics is a gene-editing company that is engaged in the development of CRISPR and Cas9-based therapeutics.
CRSP Price Action: CRISPR Therapeutics has traded as high as $220.20 and as low as $84.38 over a 52-week period.
The stock was down 8.62% at $93.75 at time of publication.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
